HIV Research Today is a free monthly online journal that collates and summarizes the latest research about HIV, including details on human immunodeficiency virus, testing, treatment, prevention, vaccines, aids.

Volume 6 (2009), Issue 10 (October)

1. Generation of a human immunodeficiency virus type 1 chronically infected monkey B cell line expressing low levels of endogenous TRIM5alpha.
   J Cell Physiol, 221(3): 760-5. [Abstract] [Full-text]
2. Toward a durable anti-HIV gene therapy based on RNA interference.
   Ann N Y Acad Sci, 1175: 3-14. [Abstract] [Full-text]
3. Up-regulation of alveolar macrophage matrix metalloproteinases in HIV1(+) smokers with early emphysema.
   J Leukoc Biol, 86(4): 913-22. [Abstract] [Full-text]
4. Obstacles to the successful development of an efficacious T cell-inducing HIV-1 vaccine.
   J Leukoc Biol, 86(4): 779-93. [Abstract] [Full-text]
5. Cationic polypeptides contribute to the anti-HIV-1 activity of human seminal plasma.
   FASEB J, 23(10): 3609-18. [Abstract] [Full-text]
6. Fast fibrosis progression between repeated liver biopsies in patients coinfected with human immunodeficiency virus/hepatitis C virus.
   Hepatology, 50(4): 1056-63. [Abstract] [Full-text]
7. Sustained and specific in vitro inhibition of HIV-1 replication by a protease inhibitor encapsulated in gp120-targeted liposomes.
   Antiviral Res, 84(2): 142-9. [Abstract] [Full-text]
8. Structural and biological mimicry of protein surface recognition by alpha/beta-peptide foldamers.
   Proc Natl Acad Sci U S A, 106(35): 14751-6. [Abstract] [Full-text]
9. HIV-1 clade C infection and progressive disruption in the relationship between cortisol, DHEAS and CD4 cell numbers: a two-year follow-up study.
   Clin Chim Acta, 409(1): 4-10. [Abstract] [Full-text]
10. From research tool to routine test: CD38 monitoring in HIV patients.
    Cytometry B Clin Cytom, 76(6): 375-84. [Abstract] [Full-text]
11. Active site remodeling switches HIV specificity of antiretroviral TRIMCyp.
    Nat Struct Mol Biol, 16(10): 1036-42. [Abstract] [Full-text]
12. Bridging the gap between adult and paediatric outcomes in HIV-1 vertically infected children: a single-centre comparison with adult data.
    Acta Paediatr, 98(11): 1787-92. [Abstract] [Full-text]
13. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target.
    Science, 326(5950): 285-9. [Abstract] [Full-text]
14. Efficient and stable transduction of resting B lymphocytes and primary chronic lymphocyte leukemia cells using measles virus gp displaying lentiviral vectors.
    Blood, 114(15): 3173-80. [Abstract] [Full-text]
15. HIV-1 Tat and heparan sulfate proteoglycan interaction: a novel mechanism of lymphocyte adhesion and migration across the endothelium.
    Blood, 114(15): 3335-42. [Abstract] [Full-text]
16. High levels of chronic immune activation in the T-cell compartments of patients coinfected with hepatitis C virus and human immunodeficiency virus type 1 and on highly active antiretroviral therapy are reverted by alpha interferon and ribavirin treatment.
    J Virol, 83(21): 11407-11. [Abstract] [Full-text]
17. Human immunodeficiency virus type 1 envelope gp120-induced partial T-cell receptor signaling creates an F-actin-depleted zone in the virological synapse.
    J Virol, 83(21): 11341-55. [Abstract] [Full-text]
18. Human immunodeficiency virus type 1 protease-correlated cleavage site mutations enhance inhibitor resistance.
    J Virol, 83(21): 11027-42. [Abstract] [Full-text]
19. A quantitative affinity-profiling system that reveals distinct CD4/CCR5 usage patterns among human immunodeficiency virus type 1 and simian immunodeficiency virus strains.
    J Virol, 83(21): 11016-26. [Abstract] [Full-text]
20. Broad neutralization of human immunodeficiency virus type 1 mediated by plasma antibodies against the gp41 membrane proximal external region.
    J Virol, 83(21): 11265-74. [Abstract] [Full-text]
21. Adaptive mutations in a human immunodeficiency virus type 1 envelope protein with a truncated V3 loop restore function by improving interactions with CD4.
    J Virol, 83(21): 11005-15. [Abstract] [Full-text]
22. X4 human immunodeficiency virus type 1 gp120 down-modulates expression and immunogenicity of codelivered antigens.
    J Virol, 83(21): 10941-50. [Abstract] [Full-text]
23. Human immunodeficiency virus type 1 is trapped by acidic but not by neutralized human cervicovaginal mucus.
    J Virol, 83(21): 11196-200. [Abstract] [Full-text]
24. Virion-associated Vpr of human immunodeficiency virus type 1 triggers activation of apoptotic events and enhances fas-induced apoptosis in human T cells.
    J Virol, 83(21): 11283-97. [Abstract] [Full-text]
25. Mechanism of human immunodeficiency virus type 1 resistance to monoclonal antibody B12 that effectively targets the site of CD4 attachment.
    J Virol, 83(21): 10892-907. [Abstract] [Full-text]
26. Human uterine natural killer cells but not blood natural killer cells inhibit human immunodeficiency virus type 1 infection by secretion of CXCL12.
    J Virol, 83(21): 11188-95. [Abstract] [Full-text]
27. Target cell type-dependent modulation of human immunodeficiency virus type 1 capsid disassembly by cyclophilin A.
    J Virol, 83(21): 10951-62. [Abstract] [Full-text]
28. Human cellular restriction factors that target HIV-1 replication.
    BMC Med, 7: 48. [Abstract] [Full-text]
29. Human immunodeficiency virus type 1 (HIV-1) protease inhibitors block cell-to-cell HIV-1 endocytosis in dendritic cells.
    J Gen Virol, 90: 2777-87. [Abstract] [Full-text]
30. Genetic and functional characterization of human immunodeficiency virus type 1 VprC variants from north India: presence of unique recombinants with mosaic genomes from B, C and D subtypes within the open reading frame of Vpr.
    J Gen Virol, 90: 2768-76. [Abstract] [Full-text]
31. Behavior of non-classical soluble HLA class G antigens in human immunodeficiency virus 1-infected patients before and after HAART: comparison with classical soluble HLA-A, -B, -C antigens and potential role in immune-reconstitution.
    Clin Immunol, 133(2): 238-44. [Abstract] [Full-text]
32. Multidrug-resistant variants of HIV type 1 (HIV-1) can exist in cells as defective quasispecies and be rescued by superinfection with other defective HIV-1 variants.
    J Infect Dis, 200(9): 1479-83. [Abstract] [Full-text]
33. Evaluation of the Abbott m2000rt RealTime HIV-1 assay with manual sample preparation compared with the ROCHE COBAS AmpliPrep/AMPLICOR HIV-1 MONITOR v1.5 using specimens from East Africa.
    J Virol Methods, 162(1): 218-22. [Abstract] [Full-text]
34. The efficiency of single genome amplification and sequencing is improved by quantitation and use of a bioinformatics tool.
    J Virol Methods, 162(1): 280-3. [Abstract] [Full-text]
35. Clinical cut-offs for HIV-1 phenotypic resistance estimates: update based on recent pivotal clinical trial data and a revised approach to viral mixtures.
    J Virol Methods, 162(1): 101-8. [Abstract] [Full-text]
36. The capsid protein of human immunodeficiency virus: interactions of HIV-1 capsid with host protein factors.
    FEBS J, 276(21): 6118-27. [Abstract] [Full-text]
37. The capsid protein of human immunodeficiency virus: designing inhibitors of capsid assembly.
    FEBS J, 276(21): 6110-7. [Abstract] [Full-text]
38. The capsid protein of human immunodeficiency virus: intersubunit interactions during virus assembly.
    FEBS J, 276(21): 6098-109. [Abstract] [Full-text]
39. Domain-elongation NMR spectroscopy yields new insights into RNA dynamics and adaptive recognition.
    RNA, 15(11): 1941-8. [Abstract] [Full-text]
40. Understanding HIV-1 latency provides clues for the eradication of long-term reservoirs.
    Nat Rev Microbiol, 7(11): 798-812. [Abstract] [Full-text]
41. Insulin-like growth factor II mRNA binding protein 1 modulates Rev-dependent human immunodeficiency virus type 1 RNA expression.
    Virology, 393(2): 210-20. [Abstract] [Full-text]
42. Immune hierarchy among HIV-1 CD8+ T cell epitopes delivered by dendritic cells depends on MHC-I binding irrespective of mode of loading and immunization in HLA-A*0201 mice.
    APMIS, 117(11): 849-55. [Abstract] [Full-text]
43. Effective activation alleviates the replication block of CCR5-tropic HIV-1 in chimpanzee CD4+ lymphocytes.
    Virology, 394(1): 109-18. [Abstract] [Full-text]
44. Cross-reactive monoclonal antibodies to multiple HIV-1 subtype and SIVcpz envelope glycoproteins.
    Virology, 394(1): 91-8. [Abstract] [Full-text]
45. Selective infection of CD4+ effector memory T lymphocytes leads to preferential depletion of memory T lymphocytes in R5 HIV-1-infected humanized NOD/SCID/IL-2Rgammanull mice.
    Virology, 394(1): 64-72. [Abstract] [Full-text]
46. Loss of raltegravir susceptibility by human immunodeficiency virus type 1 is conferred via multiple nonoverlapping genetic pathways.
    J Virol, 83(22): 11440-6. [Abstract] [Full-text]
47. Adult AIDS-like disease in a novel inducible human immunodeficiency virus type 1 Nef transgenic mouse model: CD4+ T-cell activation is Nef dependent and can occur in the absence of lymphophenia.
    J Virol, 83(22): 11830-46. [Abstract] [Full-text]
48. Antagonism to and intracellular sequestration of human tetherin by the human immunodeficiency virus type 2 envelope glycoprotein.
    J Virol, 83(22): 11966-78. [Abstract] [Full-text]
49. Crystallographic definition of the epitope promiscuity of the broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2F5: vaccine design implications.
    J Virol, 83(22): 11862-75. [Abstract] [Full-text]
50. The heptad repeat 2 domain is a major determinant for enhanced human immunodeficiency virus type 1 (HIV-1) fusion and pathogenicity of a highly pathogenic HIV-1 Env.
    J Virol, 83(22): 11715-25. [Abstract] [Full-text]
51. Inhibition of T-cell receptor-induced actin remodeling and relocalization of Lck are evolutionarily conserved activities of lentiviral Nef proteins.
    J Virol, 83(22): 11528-39. [Abstract] [Full-text]
52. Arginine methylation increases the stability of human immunodeficiency virus type 1 Tat.
    J Virol, 83(22): 11694-703. [Abstract] [Full-text]
53. Truncation of the membrane-spanning domain of human immunodeficiency virus type 1 envelope glycoprotein defines elements required for fusion, incorporation, and infectivity.
    J Virol, 83(22): 11588-98. [Abstract] [Full-text]
54. 5-Azacytidine can induce lethal mutagenesis in human immunodeficiency virus type 1.
    J Virol, 83(22): 11950-8. [Abstract] [Full-text]
55. Loss of the Brm-type SWI/SNF chromatin remodeling complex is a strong barrier to the Tat-independent transcriptional elongation of human immunodeficiency virus type 1 transcripts.
    J Virol, 83(22): 11569-80. [Abstract] [Full-text]
56. Transmission of drug-resistant HIV-1 is stabilizing in Europe.
    J Infect Dis, 200(10): 1503-8. [Abstract] [Full-text]
57. Postnatal HIV-1 transmission after cessation of infant extended antiretroviral prophylaxis and effect of maternal highly active antiretroviral therapy.
    J Infect Dis, 200(10): 1490-7. [Abstract] [Full-text]
58. New approaches for quantitating the inhibition of HIV-1 replication by antiviral drugs in vitro and in vivo.
    Curr Opin Infect Dis, 22(6): 574-82. [Abstract] [Full-text]
59. Acyclovir: a new use for an old drug.
    Curr Opin Infect Dis, 22(6): 583-7. [Abstract] [Full-text]
60. Minority variants associated with transmitted and acquired HIV-1 nonnucleoside reverse transcriptase inhibitor resistance: implications for the use of second-generation nonnucleoside reverse transcriptase inhibitors.
    J Acquir Immune Defic Syndr, 52(3): 309-15. [Abstract] [Full-text]
61. Prevention of mother-to-child transmission of HIV-1 through breastfeeding by treating mothers with triple antiretroviral therapy in Dar es Salaam, Tanzania: the Mitra Plus study.
    J Acquir Immune Defic Syndr, 52(3): 406-16. [Abstract] [Full-text]
62. Molecular characterization of a full-length genome of a HIV-2 isolate from India.
    J Acquir Immune Defic Syndr, 52(3): 329-35. [Abstract] [Full-text]
63. Frequency of long-term nonprogressors in HIV-1 seroconverters From Rakai Uganda.
    J Acquir Immune Defic Syndr, 52(3): 316-9. [Abstract] [Full-text]
64. Sustained antiretroviral effect of raltegravir after 96 weeks of combination therapy in treatment-naive patients with HIV-1 infection.
    J Acquir Immune Defic Syndr, 52(3): 350-6. [Abstract] [Full-text]
65. Impact of amino acid variations in Gag and protease of HIV type 1 CRF01_AE strains on drug susceptibility of virus to protease inhibitors.
    J Acquir Immune Defic Syndr, 52(3): 320-8. [Abstract] [Full-text]
66. Raltegravir, etravirine, and ritonavir-boosted darunavir: a safe and successful rescue regimen for multidrug-resistant HIV-1 infection.
    J Acquir Immune Defic Syndr, 52(3): 382-6. [Abstract] [Full-text]
67. Trends in post-infection CD4 cell counts and plasma HIV-1 RNA levels in HIV-1-infected patients in France between 1997 and 2005.
    J Acquir Immune Defic Syndr, 52(3): 422-6. [Abstract] [Full-text]
68. The decreased expression of Siglec-7 represents an early marker of dysfunctional natural killer-cell subsets associated with high levels of HIV-1 viremia.
    Blood, 114(18): 3822-30. [Abstract] [Full-text]
69. Potent HIV-specific responses are enriched in a unique subset of CD8+ T cells that coexpresses CD4 on its surface.
    Blood, 114(18): 3841-53. [Abstract] [Full-text]
70. Plasmacytoid dendritic cells express TRAIL and induce CD4+ T-cell apoptosis in HIV-1 viremic patients.
    Blood, 114(18): 3854-63. [Abstract] [Full-text]

© 2004-2010 HIV Research Today. All Rights Reserved.